These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 1987718

  • 1. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.
    Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO, Epstein SE.
    Am J Cardiol; 1991 Jan 15; 67(2):169-74. PubMed ID: 1987718
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
    Gilligan DM, Missouris CG, Boyd MJ, Oakley CM.
    Am J Cardiol; 1991 Oct 01; 68(9):971-3. PubMed ID: 1927963
    [No Abstract] [Full Text] [Related]

  • 5. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
    McKenna WJ, Oakley CM, Krikler DM, Goodwin JF.
    Br Heart J; 1985 Apr 01; 53(4):412-6. PubMed ID: 4039188
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
    Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ.
    Heart; 1998 Apr 01; 79(4):331-6. PubMed ID: 9616338
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring].
    Tsuchiya M, Kasanuki H, Ohnishi S, Hosoda S.
    J Cardiol; 1996 Nov 01; 28(5):267-76. PubMed ID: 8953400
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.
    Am J Cardiol; 1997 Sep 11; 80(5B):3F-9F. PubMed ID: 9291444
    [Abstract] [Full Text] [Related]

  • 11. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy.
    McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM, Goodwin JF.
    Am J Cardiol; 1984 Oct 01; 54(7):802-10. PubMed ID: 6541429
    [Abstract] [Full Text] [Related]

  • 12. Relation of left ventricular function and prognosis in hypertrophic cardiomyopathy: an angiographic study.
    Newman H, Sugrue D, Oakley CM, Goodwin JF, McKenna WJ.
    J Am Coll Cardiol; 1985 May 01; 5(5):1064-74. PubMed ID: 4039343
    [Abstract] [Full Text] [Related]

  • 13. Comparison of programmed stimulation and Holter monitoring for predicting long-term efficacy and inefficacy of amiodarone used alone or in combination with a class 1A antiarrhythmic agent in patients with ventricular tachyarrhythmia.
    Kim SG, Felder SD, Figura I, Johnston DR, Waspe LE, Fisher JD.
    J Am Coll Cardiol; 1987 Feb 01; 9(2):398-404. PubMed ID: 3805529
    [Abstract] [Full Text] [Related]

  • 14. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G, Ciaccheri M, Cecchi F, Troiani V, Nannini M, Marconi P, Olivotto J, Montereggi A, Dolara A.
    G Ital Cardiol; 1999 May 01; 29(5):514-23. PubMed ID: 10367218
    [Abstract] [Full Text] [Related]

  • 15. Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone.
    Marchlinski FE, Buxton AE, Flores BT, Doherty JU, Waxman HL, Josephson ME.
    Am J Cardiol; 1985 Mar 01; 55(6):709-12. PubMed ID: 3976513
    [Abstract] [Full Text] [Related]

  • 16. Effects of amiodarone on erect and supine exercise haemodynamics and exercise capacity in patients with hypertrophic cardiomyopathy.
    Frenneaux MP, Counihan PJ, Porter A, Lipkin DP, McKenna WJ.
    Eur Heart J; 1992 May 01; 13(5):687-96. PubMed ID: 1535589
    [Abstract] [Full Text] [Related]

  • 17. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
    McGovern B, Garan H, Malacoff RF, DiMarco JP, Grant G, Sellers TD, Ruskin JN.
    Am J Cardiol; 1984 Jun 01; 53(11):1558-63. PubMed ID: 6731300
    [Abstract] [Full Text] [Related]

  • 18. Predictive value of early electrophysiologic testing in determining long-term outcome with amiodarone treatment in patients with sustained ventricular tachycardia.
    Shannon JA, Hammill SC, Gersh BJ.
    Mayo Clin Proc; 1991 Nov 01; 66(11):1114-9. PubMed ID: 1943242
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy of the combination of low doses of beta-blockers and amiodarone in the treatment of refractory ventricular tachycardia].
    Tonet J, Frank R, Fontaine G, Grosgogeat Y.
    Arch Mal Coeur Vaiss; 1989 Sep 01; 82(9):1511-7. PubMed ID: 2573326
    [Abstract] [Full Text] [Related]

  • 20. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia.
    Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, Fragola PV, Chiarella F, Zoni-Berisso M, Branzi A.
    Circulation; 1994 Dec 01; 90(6):2743-7. PubMed ID: 7994816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.